^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    177Lu-P17-087

    i
    Other names: 177Lu-P17-087
    Associations

    News

    Trials
    Company:
    Five Eleven Pharma, Peking Union Medical College
    Drug class:
    Beta radiation emitter, PSMA inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, Peking Union Medical College Hospital | Trial completion date: Oct 2023 --> Oct 2026 | Completed --> Recruiting
    Enrollment open • Trial completion date
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression
    |
    177Lu-P17-087 • 177Lu-P17-088
    2years
    177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=9, Completed, Peking Union Medical College Hospital | Not yet recruiting --> Completed
    Trial completion • Metastases
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 overexpression
    |
    177Lu-P17-087 • 177Lu-P17-088
    3years
    177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Peking Union Medical College Hospital
    New P1 trial • Metastases
    |
    FOLH1 (Folate hydrolase 1)
    |
    FOLH1 expression • FOLH1 overexpression
    |
    177Lu-P17-087 • 177Lu-P17-088